HQ Function

The headquarters served as the primary center for CymaBay's corporate, administrative, research and development leadership, and clinical operations management prior to its acquisition by Gilead Sciences.

Notable Features:

The facility was situated in a modern business park, providing contemporary office and potentially some laboratory support space. Specific unique architectural features are not widely publicized, typical for a company of its profile.

Work Culture:

As a clinical-stage biopharmaceutical company, CymaBay's work culture likely fostered innovation, scientific excellence, collaboration, and a strong patient-focused mission. The environment would have been dynamic and driven by the goal of advancing novel therapies.

HQ Significance:

The Newark headquarters was pivotal as the command center for the development of seladelpar, coordinating global clinical trials, regulatory affairs, and strategic initiatives that ultimately led to the company's acquisition.

Values Reflected in HQ: The headquarters likely reflected values of scientific rigor, efficiency, and professionalism, designed to provide a productive and collaborative environment for its team dedicated to advancing medical treatments.

Location:

Prior to its acquisition by Gilead, CymaBay Therapeutics's global presence was primarily characterized by its international clinical trial activities for seladelpar and other pipeline candidates. These trials involved sites and patients across North America, Europe, and other key regions. The company's core corporate, R&D, and operational functions were centralized at its U.S. headquarters in Newark, California, without maintaining a network of significant physical international corporate offices. Its global reach was extended through contract research organizations (CROs) and collaborations for clinical development.

Street Address:

7999 Gateway Blvd, Suite 130

City:

Newark

State/Province:

CA

Country:

USA